Leoni F, Ciolli S, Patriarchi S, Morfini M, Rossi Ferrini P
Divisione Ematologia USL 10/D, Università degli Studi, Policlinico di Careggi, Firenze, Italia.
Acta Haematol. 1990;83(2):82-5. doi: 10.1159/000205173.
96 consecutive acute myelogenous leukemia (AML) patients were analyzed retrospectively with regard to the regimen used for remission induction. 35 patients received daunorubicin for 3 days, cytosine arabinoside and 6-thioguanine for 7 days. 61 were treated with the same regimen but 6-thioguanine was replaced by etoposide. Complete remission was achieved in 57 and 72% of patients, respectively (p = 0.06). In leukemias with monocytic phenotype (M4-M5), the remission rate was significantly higher with the etoposide-containing regimen (p = 0.02). Our findings suggest that the replacement of thioguanine by etoposide could be useful in induction therapy of AML.
对96例连续的急性髓性白血病（AML）患者进行回顾性分析，以了解其缓解诱导方案。35例患者接受柔红霉素治疗3天，阿糖胞苷和6-硫鸟嘌呤治疗7天。61例患者接受相同方案治疗，但6-硫鸟嘌呤被依托泊苷替代。两组患者的完全缓解率分别为57%和72%（p = 0.06）。在具有单核细胞表型的白血病（M4-M5）中，含依托泊苷方案的缓解率显著更高（p = 0.02）。我们的研究结果表明，用依托泊苷替代硫鸟嘌呤可能对AML的诱导治疗有用。
